Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels

Human Mutation

Volumn 35, Issue 2, 2014, Pages 208-214

  Crowley, Emily Hannah ^a   Arena, Sabrina ^a   Lamba, Simona ^a   Di Nicolantonio, Federica ^a,b   Bardelli, Alberto ^a,b,c  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

3 untranslated region; Cancer; Genetics; KRAS; Let 7; MiRNA; Single nucleotide polymorphism

Indexed keywords

K RAS PROTEIN; MICRORNA; MICRORNA 100; MICRORNA 125B; MICRORNA 141; MICRORNA LET 7; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEK293; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC VARIABILITY; HOMOLOGOUS RECOMBINATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

RATTUS;

3′ UNTRANSLATED REGION; CANCER; GENETICS; KRAS; LET-7; MIRNA; SINGLE-NUCLEOTIDE POLYMORPHISM;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; GENE KNOCK-IN TECHNIQUES; GENES, RAS; GENETIC VARIATION; HEK293 CELLS; HOMOLOGOUS RECOMBINATION; HUMANS; MICRORNAS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84891946879     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22487     Document Type: Article

References (49)

1. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Agnarsson BA, Sigurdsson A, Benediktsdottir KR, Cazier JB, Sainz J, Jakobsdottir M, Kostic J, et al. 2006. A common variant associated with prostate cancer in European and African populations. Nat Genet 38:652-658.
2. Arena S, Isella C, Martini M, de Marco A, Medico E, Bardelli A. 2007a. Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. Cancer Res 67:8468-8476.
3. Arena S, Pisacane A, Mazzone M, Comoglio PM, Bardelli A. 2007b. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc Natl Acad Sci USA 104:11412-11417.
4. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, Pasquinelli AE. 2005. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122:553-563.
5. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, Markowitz S, Willson JK, Parmigiani G, Kinzler KW, Vogelstein B, Velculescu VE. 2003. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300:949.
6. Barh D, Malhotra R, Ravi B, Sindhurani P. 2010. MicroRNA let-7: an emerging next-generation cancer therapeutic. Curr Oncol 17:70-80.
7. Bussing I, Slack FJ, Grosshans H. 2008. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med 14:400-409.
8. Cerne JZ, Stegel V, Gersak K, Novakovic S. 2012. KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer 12:105.
9. Chatterjee S, Grosshans H. 2009. Active turnover modulates mature microRNA activity in Caenorhabditis elegans. Nature 461:546-549.
10. Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. 2008. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 29:1306-1311.
11. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, et al. 2008. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 68:8535-8540.
12. Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, Marsit CJ, Kelsey KT. 2009. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis 30:1003-1007.
13. Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, et al. 2008. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci USA 105:20864-20869.
14. Esquela-Kerscher A, Slack FJ. 2006. Oncomirs-microRNAs with a role in cancer. Nat Rev 6:259-269.
15. Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, et al. 2010. Genetic modulation of the let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J 10:458-464.
16. Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, et al. 2011. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat 128:79-84.
17. Hu X, Guo J, Zheng L, Li C, Zheng TM, Tanyi JL, Liang S, Benedetto C, Mitidieri M, Katsaros D, Zhao X, Zhang Y, et al. 2013. The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res 11:240-250.
18. Iliopoulos D, Hirsch HA, Struhl K. 2009. An epigenetic switch involving NF-kappaB, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 139:693-706.
19. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. 2007. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67:7713-7722.
20. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. 2005. RAS is regulated by the let-7 microRNA family. Cell 120:635-647.
21. Kiemeney LA, Thorlacius S, Sulem P, Geller F, Aben KK, Stacey SN, Gudmundsson J, Jakobsdottir M, Bergthorsson JT, Sigurdsson A, Blondal T, Witjes JA, et al., 2008. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet 40:1307-1312.
22. Mayr C, Hemann MT, Bartel DP. 2007. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315:1576-1579.
23. Nelson HH, Christensen BC, Plaza SL, Wiencke JK, Marsit CJ, Kelsey KT. 2010. KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. Lung Cancer 69:51-53.
24. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, et al. 2011. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 12:377-386.
25. Permuth-Wey J, Chen Z, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Chanock SJ, Cramer DW, Cunningham JM, Fenstermacher D, Fridley BL, et al. 2011. MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 20:1793-1797.
26. Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D; BCFR Investigations, Beattie MS, Beckmann MW, et al. 2011. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res 17:3742-3750.
27. Prior IA, Lewis PD, Mattos C. 2012. A comprehensive survey of Ras mutations in cancer. Cancer Res 72:2457-2467.
28. Ramachandran V, Chen X. 2008. Degradation of microRNAs by a family of exoribonucleases in Arabidopsis. Science 321:1490-1492.
29. Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller R-U, et al. 2011. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 31:4559-4566.
30. Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, et al. 2010. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res 70:6509-6515.
31. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. 2000. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403:901-906.
32. Roush S, Slack FJ. 2008. The let-7 family of microRNAs. Trends Cell Biol 18:505-516.
33. Salzman DW, Weidhaas JB. 2011. miRNAs in the spotlight: making 'silent' mutations speak up. Nat Med 17:934-935.
34. Salzman DW, Weidhaas JB. 2013. SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther 137:55-63.
35. Schumacher FR, Feigelson HS, Cox DG, Haiman CA, Albanes D, Buring J, Calle EE, Chanock SJ, Colditz GA, Diver WR, Dunning AM, Freedman ML, et al. 2007. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res 67:2951-2956.
36. Shi XB, Tepper CG, deVere White RW. 2008. Cancerous miRNAs and their regulation. Cell Cycle 7:1529-1538.
37. Shitara M, Sasaki H, Yokota K, Okuda K, Hikosaka Y, Moriyama S, Yano M, Kawaguchi T, Kubo A, Takada M, Kitahara N, Okumura M, et al. 2012. Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients. Exp Ther Med 4:785-789.
38. Smits KM, Paranjape T, Nallur S, Wouters KA, Weijenberg MP, Schouten LJ, van den Brandt PA, Bosman FT, Weidhaas JB, van Engeland M. 2011. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 17:7723-7731.
39. Sur IK, Hallikas O, Vaharautio A, Yan J, Turunen M, Enge M, Taipale M, Karhu A, Aaltonen LA, Taipale J. 2012. Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science 338:1360-1363.
40. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T, et al. 2004. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753-3756.
41. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, Gocayne JD, Amanatides P, et al. 2001. The sequence of the human genome. Science 291:1304-1351.
42. Wang Y, Sheng G, Juranek S, Tuschl T, Patel DJ. 2008. Structure of the guide-strand containing argonaute silencing complex. Nature 456:209-213.
43. Xing JC, Tufano RP, Murugan AK, Liu D, Wand G, Ladenson PW, Xing M, Trink B. 2012. Single nucleotide polymorphism rs17849071 G/T in the PIK3CA gene is inversely associated with follicular thyroid cancer and PIK3CA amplification. PloS One 7:e49192.
44. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, Harris CC. 2006. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189-198.
45. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E. 2007. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131:1109-1123.
46. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E, Ferretti V, Laflamme P, et al. 2007. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39:989-994.
47. Zecchin D, Di Nicolantonio F. 2011. Transfection and DNA-mediated gene transfer. Methods Mol Biol 731:435-450.
48. Zhang L, Yuan X, Chen Y, Du XJ, Yu S, Yang M. 2013. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib. Gene 517:60-64.
49. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. 2010. A let-7 microRNA-binding site polymorphism in 3'- untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 22:104-109.